Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25,524 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment Phase 1 Clear all
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on Bioavailability of MDMA in Healthy Volunteers

NCT05147402
View directory record Official record
Conditions
Pharmacokinetics
Interventions
midomafetamine
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

CHFR Methylation Status Esophageal Cancer Study

NCT01372202
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Paclitaxel, Cisplatin, Oxaliplatin, 5-Fluorouracil, Radiotherapy, Esophagectomy
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

NCT05191472
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Pembrolizumab
Biological
Lead sponsor
Alfred Chung, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

NCT02271945
View directory record Official record
Conditions
Relapsed/Refractory Aggressive B-cell Lymphomas
Interventions
MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

NCT01055795
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Bevacizumab, Everolimus and LBH589
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

NCT00602277
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Wild-type Reovirus
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

NCT00437957
View directory record Official record
Conditions
Brain Metastases
Interventions
Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 26, 2026, 2:17 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
View directory record Official record
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741
View directory record Official record
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00053183
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
conventional surgery, brachytherapy, radiation therapy
Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

NCT01686256
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 26, 2026, 2:17 AM EDT
Not listed Phase 1 Interventional

A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors

NCT01315431
View directory record Official record
Conditions
Solid Tumor
Interventions
Tesetaxel plus capecitabine
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

NCT00661531
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast, Neoplasms, Breast
Interventions
Estrace, Anastrozole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity

NCT03307837
View directory record Official record
Conditions
Hallux Valgus Deformity
Interventions
CA-008, Placebo
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60

NCT02280395
View directory record Official record
Conditions
Postoperative Wound Infection-deep, Post Operative Wound Infection
Interventions
RUT058-60, Sterile saline for irrigation
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Mobile, Alabama • La Jolla, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

NCT01052077
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 26, 2026, 2:17 AM EDT
Suspended Phase 2 Interventional

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

NCT06069375
View directory record Official record
Conditions
Medium-chain Acyl-CoA Dehydrogenase Deficiency
Interventions
Sodium phenylbutyrate
Drug
Lead sponsor
Jerry Vockley, MD, PhD
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions
PY314, Combination Therapy: PY314 + Pembrolizumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Oral ONC201 in Treating Patients With Advanced Solid Tumors

NCT02250781
View directory record Official record
Conditions
Solid Tumors
Interventions
Oral ONC201
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

NCT00841100
View directory record Official record
Conditions
Phenylketonuria
Interventions
Kuvan, Diet
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
4 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

NCT00532883
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

NCT01458366
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Ofatumumab, Carboplatin, Etoposide, CT Scan, PET Scan, Stem Cell Transplant (STC)
Drug · Procedure · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Stereotactic Body Radiotherapy for Head and Neck Tumors

NCT01344356
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma, Paraganglioma of Head and Neck, Chordoma of Head and Neck, Chondrosarcoma of Head and Neck, Angiofibroma of Head and Neck
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 26, 2026, 2:17 AM EDT